Radiopharm Theranostics Limited: December 2024 Form 6-K Report on RAD 202 Trial Approval

Here's the key information extracted from the financial report:

Company Information:

• Name: Radiopharm Theranostics Limited
• Commission File Number: 001-41621
• Address: Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia

Filing Details:

• Type of Filing: Form 6-K
• Period Covered: For the Month of December 2024
• Date of Filing: December 20, 2024

Announcement:

• The company published a public notice to the Australian Securities Exchange titled:
• Title: “RAD 202 receives approval to start Phase 1 therapeutic trial”
• A copy of this public notice is attached to the report as an exhibit.

Compliance Notes:

• The filing shall not be deemed "filed" for the purposes of the Securities Exchange Act of 1934 and will not be incorporated by reference into any filing under the Securities Act of 1933, unless stated otherwise.

Signature:

• Authorized Signatory: Phillip Hains
• Position: Company Secretary
• Date Signed: December 20, 2024

Exhibit Details:

• Exhibit Number: 99.1
• Exhibit Description: "RAD 202 receives approval to start Phase 1 therapeutic trial"

Insights:

• The approval for the Phase 1 therapeutic trial of RAD 202 is a significant development for Radiopharm Theranostics Limited, potentially indicating progress in their research and development pipeline. This could have implications for future revenues and market positioning, depending on the outcomes of the trials.

This report provides a snapshot of the company's regulatory compliance and highlights a crucial advancement in its therapeutic development efforts.